AAPL 242.195 -3.2845% MSFT 415.4 -1.4472% NVDA 136.11 1.3553% GOOGL 188.45 -0.449% GOOG 189.67 -0.4043% AMZN 218.77 -0.2826% META 592.1525 1.1345% AVGO 230.54 -0.5607% TSLA 377.02 -6.6412% TSM 199.64 1.0887% LLY 774.59 0.3355% V 312.71 -1.0537% JPM 239.57 -0.0584% UNH 504.27 -0.3143% NVO 87.56 1.7903% WMT 89.7 -0.7194% LVMUY 128.99 -1.3008% XOM 107.02 -0.5113% LVMHF 645.0 -1.7816% MA 518.315 -1.5677%
Last update at 2025-01-02T18:52:00Z
Merck buys cancer therapy developer Modifi Biosciences for up to $1.3 bln
Wed 23 Oct 24, 12:43 PMNOVUS Leverages Ginkgo Bioworks to Develop Innovative Feed Additives for Animal Agriculture
Tue 24 Sep 24, 11:01 AMGinkgo Bioworks Launches New Protein LLM and Model API Built on Google Cloud Technology
Tue 17 Sep 24, 12:01 PMGinkgo Regains Compliance with NYSE Minimum Bid Price Requirement
Wed 04 Sep 24, 08:30 PMThis 1 AI Stock Could Revolutionize Biotech and Pharma
Mon 02 Sep 24, 09:11 AMUpcoming Stock Splits This Week (August 19 to August 23) – Stay Invested
Mon 19 Aug 24, 11:56 AMGinkgo Bioworks Holdings Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Tue 13 Aug 24, 07:02 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Income before tax | -2121.39900M | -1838.12200M | -124.83400M | -119.83500M |
| Minority interest | 1.44M | -6.59500M | 8.68M | 8.79M |
| Net income | -2106.37200M | -1836.64200M | -126.72300M | -119.85700M |
| Selling general administrative | 1429.80M | 862.95M | 38.31M | 29.48M |
| Selling and marketing expenses | - | - | - | - |
| Gross profit | 273.49M | 184.15M | 61.05M | 54.18M |
| Reconciled depreciation | 44.42M | 29.08M | 13.86M | 10.76M |
| Ebit | -2208.95200M | -1828.46700M | -137.02700M | -71.59800M |
| Ebitda | -2180.39400M | -1877.57100M | -107.51500M | -81.04600M |
| Depreciation and amortization | 28.56M | -49.10400M | 29.51M | -9.44800M |
| Non operating income net other | 87.55M | - | - | - |
| Operating income | -2208.95200M | -1828.46700M | -137.02700M | -71.59800M |
| Other operating expenses | 2686.66M | 2142.30M | 213.68M | 125.78M |
| Interest expense | 0.11M | 2.37M | 2.38M | 2.42M |
| Tax provision | -15.02700M | -1.48000M | 1.89M | 0.02M |
| Interest income | 20.26M | 0.84M | 2.58M | 5.76M |
| Net interest income | 20.16M | -1.53600M | 0.20M | 3.33M |
| Extraordinary items | - | - | - | - |
| Non recurring | - | - | - | - |
| Other items | - | - | - | - |
| Income tax expense | -15.02700M | -1.48000M | 1.89M | 0.02M |
| Total revenue | 477.71M | 313.84M | 76.66M | 54.18M |
| Total operating expenses | 2482.44M | 2012.61M | 198.07M | 125.78M |
| Cost of revenue | 204.22M | 129.69M | 15.61M | 0.00000M |
| Total other income expense net | 87.55M | -9.65500M | 12.19M | -48.23700M |
| Discontinued operations | - | - | - | - |
| Net income from continuing ops | -2106.37200M | -1836.64200M | -126.72300M | -119.85700M |
| Net income applicable to common shares | -2104.92900M | -1830.04700M | -126.60900M | -119.32700M |
| Preferred stock and other adjustments | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 2539.32M | 2070.99M | 675.15M | 697.32M |
| Intangible assets | 111.04M | 21.64M | 3.29M | 3.84M |
| Earning assets | - | - | - | - |
| Other current assets | 49.02M | 0.70M | 1.44M | 5.30M |
| Total liab | 803.04M | 503.61M | 205.10M | 204.25M |
| Total stockholder equity | 1736.28M | 1505.37M | 461.38M | 493.06M |
| Deferred long term liab | 174.77M | 174.74M | - | - |
| Other current liab | 114.69M | 92.58M | 30.02M | 23.44M |
| Common stock | 0.19M | 0.16M | 0.13M | 0.08M |
| Capital stock | 0.19M | 0.16M | 0.13M | - |
| Retained earnings | -4397.65900M | -2297.92500M | -467.87800M | -341.26900M |
| Other liab | 216.83M | 346.57M | 115.36M | 138.62M |
| Good will | 60.21M | 21.31M | 1.86M | 1.86M |
| Other assets | 88.72M | 43.99M | 18.90M | 9.31M |
| Cash | 1315.79M | 1550.00M | 380.80M | - |
| Cash and equivalents | 1315.79M | 1550.00M | 380.80M | 495.29M |
| Total current liabilities | 172.96M | 134.76M | 73.22M | 40.07M |
| Current deferred revenue | 47.82M | 33.24M | 28.82M | - |
| Net debt | -902.53600M | -1526.97400M | -363.79800M | - |
| Short term debt | 29.33M | 0.75M | 0.48M | 0.00000M |
| Short long term debt | - | - | - | - |
| Short long term debt total | 413.26M | 23.03M | 17.00M | - |
| Other stockholder equity | 6133.75M | 3804.84M | 929.12M | - |
| Property plant equipment | 715.53M | 145.77M | 121.44M | 63.13M |
| Total current assets | 1450.08M | 1723.05M | 426.54M | 511.93M |
| Long term investments | 113.73M | 102.04M | 103.12M | - |
| Net tangible assets | 1565.03M | 1462.41M | 456.04M | 487.19M |
| Short term investments | - | - | - | - |
| Net receivables | 80.91M | 149.90M | 24.17M | 8.78M |
| Long term debt | - | - | - | - |
| Inventory | 4.36M | 3.36M | 2.74M | 0.00000M |
| Accounts payable | 10.45M | 8.19M | 13.89M | 2.44M |
| Total permanent equity | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | 62.01M | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - |
| Accumulated other comprehensive income | -2.63200M | -1.71500M | - | - |
| Additional paid in capital | - | - | - | - |
| Common stock total equity | 0.19M | 0.16M | - | - |
| Preferred stock total equity | - | - | - | - |
| Retained earnings total equity | -4397.65900M | -2297.92500M | - | - |
| Treasury stock | - | - | - | - |
| Accumulated amortization | - | - | - | - |
| Non currrent assets other | 202.46M | 43.99M | 5.60M | - |
| Deferred long term asset charges | - | - | - | - |
| Non current assets total | 1089.24M | 347.94M | 248.61M | - |
| Capital lease obligations | 413.26M | 23.03M | 17.00M | - |
| Long term debt total | 0.00000M | 22.28M | 16.52M | 16.77M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | -67.39400M | -5.00000M | -67.12100M | -50.13300M |
| Change to liabilities | -50.45200M | -12.74500M | -12.40400M | 5.55M |
| Total cashflows from investing activities | -67.39400M | -73.25700M | -67.12100M | -74.60200M |
| Net borrowings | 97.84M | -1.12300M | -0.74800M | 198.60M |
| Total cash from financing activities | 95.34M | 1534.14M | 90.32M | 410.38M |
| Change to operating activities | -44.93300M | 65.93M | 2.85M | 6.87M |
| Net income | -2106.37200M | -1836.64200M | -126.72300M | -119.85700M |
| Change in cash | -223.34700M | 1207.05M | -112.63300M | 291.12M |
| Begin period cash flow | 1592.93M | 385.88M | 498.51M | 207.39M |
| End period cash flow | 1369.58M | 1592.93M | 385.88M | 498.51M |
| Total cash from operating activities | -252.19800M | -253.81800M | -135.83000M | -44.66300M |
| Issuance of capital stock | 99.30M | 0.00000M | 91.04M | 212.18M |
| Depreciation | 44.42M | 29.08M | 13.86M | 10.76M |
| Other cashflows from investing activities | -15.12300M | -16.73600M | -9.30000M | -52.38300M |
| Dividends paid | - | - | - | - |
| Change to inventory | 0.16M | -0.62600M | -2.73600M | -2.22200M |
| Change to account receivables | 55.02M | -114.09400M | -14.22800M | -1.84300M |
| Sale purchase of stock | 99.54M | -24.99800M | 91.07M | -0.40800M |
| Other cashflows from financing activities | -2.72900M | 1560.27M | 91.07M | 411.62M |
| Change to netincome | 1859.54M | 1608.69M | 3.43M | 53.33M |
| Capital expenditures | 52.27M | 56.52M | 57.82M | 22.22M |
| Change receivables | 55.02M | -114.09400M | - | - |
| Cash flows other operating | -58.80900M | -34.69500M | - | - |
| Exchange rate changes | - | - | - | - |
| Cash and cash equivalents changes | -224.25500M | 1207.07M | - | - |
| Change in working capital | -37.00600M | -61.53700M | -26.51500M | 10.58M |
| Stock based compensation | 1930.64M | 1606.02M | 0.48M | 0.77M |
| Other non cash items | -69.27500M | -20.94700M | -1.06100M | -1.64200M |
| Free cash flow | -304.46900M | -310.33900M | -193.65100M | -66.88200M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| DNA Ginkgo Bioworks Holdings |
0.38 3.87% | 10.20 | - | - | 11.43 | 2.88 | 9.38 | -4.4915 |
| NVO Novo Nordisk A/S |
1.54 1.79% | 87.56 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
1.10 1.28% | 87.00 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
0.28 0.07% | 402.98 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
-0.075 0.01% | 712.25 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
27 Drydock Avenue, Boston, MA, United States, 02210
| Name | Title | Year Born |
|---|---|---|
| Dr. Jason Kelly | Founder, CEO & Director | 1981 |
| Dr. Reshma P. Shetty | Founder, Pres, COO & Director | 1981 |
| Mr. Mark E. Dmytruk | Chief Financial Officer | 1971 |
| Mr. Thomas Knight Jr. | Founder | NA |
| Mr. Austin Che | Founder, Head of Strategy & Treasurer | NA |
| Mr. Bartholomew Canton | Founder, CTO & Sec. | NA |
| Marie E Fallon | Chief Accounting Officer | NA |
| Karen Tepichin | Gen. Counsel & Sec. | NA |
| Ms. Anna Marie Wagner | Sr. VP of Corp. Devel. | NA |
| Ms. Samantha Sutton | Head of People | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...